Search

everythinglearnresearchcommunity

for

Search:↓

Researchers found three different ways drugs work to treat hair loss from alopecia areata and identified key factors for personalized treatment.

Researchers found that most genes affecting drug responses are not fully covered by commercial SNP chips, suggesting the need for more comprehensive tools to optimize drug selection based on genetics.

Different drug doses approved in Japan and the U.S. are not mainly due to different clinical responses, and ethnic factors should be considered in setting drug doses.

Researchers found a specific immune receptor in patients that causes severe skin reactions to a drug.

Machine learning can predict how well patients with alopecia areata will respond to certain treatments.

The model can effectively test gene functions and drug responses in human skin.

The conclusion is that combining social and cultural factors with pharmaceutical research could improve our understanding of how drugs work.

High-content screening is useful for finding new treatments for rare diseases and has led to FDA-approved drugs.

A cancer patient's eyelashes grew excessively without other common side effects after taking the cancer drug erlotinib.

Organoid technology is advancing and entering commercial use, with applications in disease modeling, drug development, and personalized medicine.

The new method makes it easier to study the whole cochlea from newborn mice and rats in the lab.

The study identified key genes and pathways linked to hair disorders, aiding precision medicine.

Hair follicle culture helps study hair growth but has limitations in modeling the full hair cycle.

Low doses of some substances can be beneficial, while high doses can be harmful or toxic.

The document concludes that side effects from Smoothened inhibitor drugs for skin cancer are reversible and can be managed with a team approach to maintain quality of life.

Melanocytes are important for normal body functions and have potential uses in regenerative medicine and disease treatment.

Scientists identified three genes important for processing certain brain chemicals, thyroid hormones, and medications.

The document concludes that inhalation of oxygen and sumatriptan injections are primary for cluster headaches, indomethacin for paroxysmal hemicrania, and lidocaine and lamotrigine for SUNCT, but SUNCT often resists treatment.

Human hair follicles may provide a noninvasive way to diagnose diseases and have potential in regenerative medicine.

Advanced human skin models improve drug development and could replace animal testing.

Drug repositioning is becoming more targeted and efficient with new technologies, offering personalized treatment options and growing interest in the field.

Dermal papilla microtissues could be useful for initial hair growth drug testing.

Genetic variations affect dutasteride treatment response for male pattern hair loss.

The document concludes that various skin conditions have specific treatments, ranging from antihistamines for urticaria to surgery and medication for tumors and chronic skin diseases.

STK11 gene variations do not predict how well metformin will work for PCOS, but may affect hair loss and excess hair growth.

Understanding how EDC genes are regulated can help develop better drugs for skin diseases.

Modulating Cytochrome P450 activity could help develop new skin disease treatments.

A man's rash caused by Finasteride improved after stopping the drug and starting new treatments.

Certain existing drugs, like glycopyrronium and botulinum toxin type A, may help treat excessive sweating.

Some natural compounds may help overcome drug resistance in certain cancers, but more research is needed.